急性脳梗塞(AIS)治療薬の世界市場2017-2021

【英語タイトル】Global Acute Ischemic Stroke Therapeutics Market 2017-2021

Technavioが出版した調査資料(IRTNTR14174)・商品コード:IRTNTR14174
・発行会社(調査会社):Technavio
・発行日:2017年8月9日
・ページ数:84
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:医療・バイオ
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥378,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥540,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、急性脳梗塞(AIS)治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、急性脳梗塞(AIS)治療薬の世界市場規模及び予測、地域別分析/市場規模、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。Technavio社は急性脳梗塞(AIS)治療薬の世界市場が2017-2021年期間中に年平均2.11%成長すると予測しています。当レポート上に記載されている主な企業は• Bayer • Boehringer Ingelheim • F. Hoffmann-La Roche• Sanofi等です。
【レポートの概要】

About Acute Ischemic Stroke Therapeutics
AIS is a chronic condition characterized by the sudden loss of blood supply to a part of the brain, thus causing subsequent loss of neurological function. AIS is caused by thrombotic or embolic obstruction of the cerebral artery and is more common than hemorrhagic stroke. The global AIS therapeutics market is expected to register a low single digit market growth during the forecast period. The marginal growth rate is attributed to the lack of approved drugs in this area, the presence of alternative therapies, extensive use of generics, and unmet needs for anticoagulant reversal agents.

Technavio’s analysts forecast the global acute ischemic stroke therapeutics market to grow at a CAGR of 2.11% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global acute ischemic stroke therapeutics market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs from various drug classes.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Acute Ischemic Stroke Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Bayer
• Boehringer Ingelheim
• F. Hoffmann-La Roche
• Sanofi

[Other prominent vendors]
• Biogen
• Daiichi Sankyo
• Pfizer

[Market driver]
• Increasing adoption of NOACs
• For a full, detailed list, view our report

[Market challenge]
• Unmet needs for anticoagulant reversal agents
• For a full, detailed list, view our report

[Market trend]
• TBI, a value-addition in AIS research
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Market outline

PART 05: Acute ischemic stroke (AIS): An overview
• Ischemia
• IHD
• Stroke
• AIS

PART 06: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 07: Pipeline landscape

PART 08: Market segmentation by drug-class
• Thrombolytic therapeutics
• Antihypertensive therapeutics
• Antiplatelet therapeutics
• Anticoagulants
• Others

PART 09: Geographical segmentation
• Market overview based on geography
• AIS therapeutics market in Americas
• AIS therapeutics market in EMEA
• AIS therapeutics market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges
• Market drivers
• Market challenges

PART 12: Market trends
• TBI, a value-addition in AIS research
• Advent of genomic medicine

PART 13: Vendor landscape
• Competitive scenario
• Key news

PART 14: Key vendor analysis
• Bayer
• Boehringer Ingelheim
• F. Hoffmann-La Roche
• Sanofi
• Other prominent vendors

PART 15: Appendix
• List of abbreviations

[List of Exhibits] Exhibit 01: Symptoms of AIS
Exhibit 02: Global AIS therapeutics market: Snapshot
Exhibit 03: Global AIS therapeutics market 2016-2021 ($ millions)
Exhibit 04: Mechanism of action of alteplase
Exhibit 05: Global AIS therapeutics market: Opportunity analysis
Exhibit 06: Five forces analysis
Exhibit 07: Pipeline snapshot
Exhibit 08: Key clinical trials
Exhibit 09: Global AIS therapeutics market segmentation by drug-class
Exhibit 10: Global AIS therapeutics market share by drug-class 2016
Exhibit 11: Global AIS thrombolytic therapeutics market 2016-2021 ($ millions)
Exhibit 12: Global AIS antihypertensive therapeutics market 2016-2021 ($ millions)
Exhibit 13: Global AIS antiplatelet therapeutics market 2016-2021 ($ millions)
Exhibit 14: Global AIS anticoagulant therapeutics market 2016-2021 ($ millions)
Exhibit 15: Global AIS therapeutics market share by geography 2016 and 2021
Exhibit 16: Global AIS therapeutics market by geography 2016-2021 ($ millions)
Exhibit 17: Global AIS therapeutics market by geography 2016-2021 (% share)
Exhibit 18: AIS therapeutics market scenario in different geographies
Exhibit 19: Market scenario in Americas
Exhibit 20: Stroke scenario in US: An overview
Exhibit 21: AIS therapeutics market in Americas 2016-2021 ($ millions)
Exhibit 22: Market scenario in EMEA
Exhibit 23: AIS therapeutics market in EMEA 2016-2021 ($ millions)
Exhibit 24: Market scenario in APAC
Exhibit 25: AIS therapeutics market in APAC 2016-2021 ($ millions)
Exhibit 26: Prevalence of stroke in US
Exhibit 27: ACTIVASE regional sales 2015 and 2016
Exhibit 28: Prevalence of obesity among US adults in 2015
Exhibit 29: Competitive structure analysis of global AIS therapeutics market 2016
Exhibit 30: Bayer: Key highlights
Exhibit 31: Bayer: Strength assessment
Exhibit 32: Bayer: Strategy assessment
Exhibit 33: Bayer: Opportunity assessment
Exhibit 34: Boehringer Ingelheim: Key highlights
Exhibit 35: Boehringer Ingelheim: Strength assessment
Exhibit 36: Boehringer Ingelheim: Strategy assessment
Exhibit 37: Boehringer Ingelheim: Opportunity assessment
Exhibit 38: F. Hoffmann-La Roche: Key highlights
Exhibit 39: F. Hoffmann-La Roche: Strength assessment
Exhibit 40: F. Hoffmann-La Roche: Strategy assessment
Exhibit 41: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 42: Sanofi: Key highlights
Exhibit 43: Sanofi: Strength assessment
Exhibit 44: Sanofi: Strategy assessment
Exhibit 45: Sanofi: Opportunity assessment



【掲載企業】

Bayer, Boehringer Ingelheim, F. Hoffmann-La Roche, Sanofi, Biogen, Daiichi Sankyo, and Pfizer.


【レポートのキーワード】

急性脳梗塞(AIS)、急性脳梗塞治療薬

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[急性脳梗塞(AIS)治療薬の世界市場2017-2021] (コード:IRTNTR14174)販売に関する免責事項を必ずご確認ください。
★調査レポート[急性脳梗塞(AIS)治療薬の世界市場2017-2021]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆